Indoco Remedies 過去の業績
過去 基準チェック /16
Indoco Remediesは、平均年間13.4%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.3% 11.6%収益成長率で 成長しています。 Indoco Remediesの自己資本利益率は2.7%であり、純利益率は1.8%です。
主要情報
13.4%
収益成長率
13.1%
EPS成長率
| Pharmaceuticals 業界の成長 | 17.5% |
| 収益成長率 | 11.6% |
| 株主資本利益率 | 2.7% |
| ネット・マージン | 1.8% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Oct 27
Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
May 24Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
Jan 26Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Jan 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Sep 16Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
May 21Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Aug 31Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Jul 04Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Jul 02Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Jun 10Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Mar 25Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price
Mar 09What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?
Feb 22Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?
Feb 07Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 17Is Indoco Remedies (NSE:INDOCO) A Risky Investment?
Dec 27
Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)
Dec 06What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?
Nov 14収支内訳
収支内訳
Indoco Remedies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 17,732 | 321 | 4,685 | 875 |
| 30 Jun 24 | 18,223 | 767 | 3,677 | 980 |
| 31 Mar 24 | 18,173 | 985 | 4,621 | 972 |
| 31 Dec 23 | 17,958 | 1,016 | 4,219 | 979 |
| 30 Sep 23 | 17,356 | 1,134 | 4,141 | 936 |
| 30 Jun 23 | 16,869 | 1,281 | 3,307 | 866 |
| 31 Mar 23 | 16,686 | 1,423 | 3,941 | 810 |
| 31 Dec 22 | 16,496 | 1,569 | 3,718 | 766 |
| 30 Sep 22 | 16,084 | 1,617 | 3,616 | 738 |
| 30 Jun 22 | 15,622 | 1,537 | 3,014 | 764 |
| 31 Mar 22 | 15,408 | 1,548 | 3,435 | 746 |
| 31 Dec 21 | 14,368 | 1,393 | 3,407 | 714 |
| 30 Sep 21 | 14,110 | 1,317 | 3,423 | 716 |
| 30 Jun 21 | 13,524 | 1,157 | 2,832 | 660 |
| 31 Mar 21 | 12,415 | 930 | 3,341 | 597 |
| 31 Dec 20 | 12,084 | 734 | 3,372 | 573 |
| 30 Sep 20 | 11,654 | 571 | 3,326 | 529 |
| 30 Jun 20 | 11,298 | 393 | 2,614 | 488 |
| 31 Mar 20 | 11,066 | 241 | 3,167 | 497 |
| 31 Dec 19 | 10,909 | 302 | 2,916 | 488 |
| 30 Sep 19 | 10,640 | 264 | 2,825 | 483 |
| 30 Jun 19 | 10,071 | 111 | 2,767 | 494 |
| 31 Mar 19 | 9,684 | -29 | 2,721 | 515 |
| 31 Mar 18 | 10,424 | 412 | 2,637 | 535 |
| 31 Mar 17 | 10,968 | 771 | 2,605 | 517 |
| 31 Mar 16 | 10,081 | 819 | 2,141 | 432 |
| 31 Mar 15 | 8,570 | 828 | 1,664 | 217 |
| 31 Mar 14 | 7,336 | 580 | 2,616 | 208 |
質の高い収益: INDOCO 非現金収入 のレベルが高いです。
利益率の向上: INDOCOの現在の純利益率 (1.8%)は、昨年(6.5%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: INDOCOの収益は過去 5 年間で年間13.4%増加しました。
成長の加速: INDOCOは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。
収益対業界: INDOCOは過去 1 年間で収益成長率がマイナス ( -71.7% ) となったため、 Pharmaceuticals業界平均 ( 20.5% ) と比較することが困難です。
株主資本利益率
高いROE: INDOCOの 自己資本利益率 ( 2.7% ) は 低い とみなされます。